Phenazepam's safety pharmacogenetic study results: influence of CYP2C9, CYP3A5, CYP2C19, ABCB1 and CYP3A4/5 isoenzymes' activity

被引：0
|
作者：
Ivashchenko, D. [1 ]
Ryzhikova, K. [2 ]
Sozaeva, Z. [2 ]
Grishina, E. [2 ]
Zastrozhin, M. [3 ]
Bryun, E. [3 ]
Sychev, D. [4 ]
机构：
[1] Russian Med Acad Continuous Profess Educ, Dept Appl Problems Personalized Med, Moscow, Russia
[2] Russian Med Acad Continuous Profess Educ, Dept Mol Biol Studies, Moscow, Russia
[3] Russian Med Acad Continuous Profess Educ, Dept Narcol, Moscow, Russia
[4] Russian Med Acad Continuous Profess Educ, Dept Clin Pharmacol, Moscow, Russia
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2018年 / 28卷
关键词：
D O I：
10.1016/j.euroneuro.2017.12.037
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.1.019
引用
收藏
页码：S17 / S18
页数：2
相关论文
共 50 条
  • [21] Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans
    Krulikas, Linas
    Bates, Jill
    Chanfreau, Catherine
    Coleman, Heather
    Dalton, Shawn
    Voora, Deepak
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (02) : 390 - 396
  • [22] CYP2C9, CYP2C19, and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity
    Hennessy, Sean
    Leonard, Charles E.
    Freeman, Cristin P.
    Metlay, Joshua P.
    Chu, Xin
    Strom, Brian L.
    Bilker, Warren B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (12): : 1483 - 1487
  • [23] CYP2C9, CYP2C19 and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity
    Hennessy, Sean
    Leonard, Charles E.
    Palumbo, Cristin M.
    Metlay, Joshua P.
    Chu, Xin
    Strom, Brian L.
    Bilker, Warren B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S22 - S22
  • [24] Pharmacogenetics of CYP3A4, CYP3A5, CYP2C8 and CYP2C19 and Their Influence on Tacrolimus Pharmacokinetics in Renal Transplant Recipients.
    Wang, Z.
    Han, Z.
    Tao, J.
    Chen, H.
    Sun, L.
    Tan, R.
    Gu, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 672 - 672
  • [25] Effect of genetic variants in CYP2C8, CYP3A4, CYP3A5, and ABCB1 on paclitaxel pharmacokinetics.
    Sparreboom, A
    Marsh, S
    Henningsson, A
    Karlsson, MO
    Garsa, A
    Loos, WJ
    Verweij, J
    McLeod, HL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 139S - 139S
  • [26] A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, and VKORC1 Genes
    Tron, Camille
    Bouvet, Regis
    Verdier, Marie-Clemence
    Lamoureux, Fabien
    Hennart, Benjamin
    Dubourg, Christele
    Bellissant, Eric
    Galibert, Marie-Dominique
    PHARMACEUTICALS, 2022, 15 (05)
  • [27] An easy, fast and inexpensive multiplex pharmacogenetics assay to simultaneously analyze 17 clinically relevant genetic polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1 and VKORC1 genes
    Tron, C.
    Bouvet, R.
    Verdier, M. C.
    Lamoureux, F.
    Hennart, B.
    Dubourg, C.
    Bellissant, E.
    Galibert, M. D.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 55 - 56
  • [28] INFLUENCES OF CYTOCHROME B5 EXPRESSION AND ITS GENETIC POLYMORPHISM ON THE ACTIVITY OF CYP2C9, CYP2C19 AND CYP3A4
    Yoo, Sung-Eun
    Yi, Myeongjin
    Cho, Sun-Ah
    Kim, Woo-Young
    Kim, Dong-Hyun
    Shin, Jae-Gook
    Lee, Su-Jun
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S40 - S40
  • [29] Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4
    Yoo, Sung-Eun
    Yi, MyeongJin
    Kim, Woo-Young
    Cho, Sun-Ah
    Lee, Sang Seop
    Lee, Su-Jun
    Shin, Jae-Gook
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (03) : 201 - 208
  • [30] Effect of fifteen CYP3A4 in vitro inducers on the induction of CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP3A5 in plated human hepatocytes: a trend analysis
    Zhang, J. George
    Patel, Reena
    Clark, Robert J.
    Ho, Thuy
    Trisdale, Sarah K.
    Stresser, David M.
    DRUG METABOLISM REVIEWS, 2016, 48 : 84 - 84
12345